These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11948003)

  • 1. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers.
    Dutta S; Zhang Y; Selness DS; Lee LL; Williams LA; Sommerville KW
    Epilepsy Res; 2002 Mar; 49(1):1-10. PubMed ID: 11948003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
    Garikipati V; Toops DS; Fang Q
    Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.
    Citrome L; Tremeau F; Wynn PS; Roy B; Dinakar H
    J Clin Psychopharmacol; 2004 Jun; 24(3):255-9. PubMed ID: 15118478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.
    Davis LL; Li X; Bartolucci AA; Williford RB; Lowe JS
    J Clin Psychiatry; 2007 Oct; 68(10):1546-51. PubMed ID: 17960970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
    Dutta S; Zhang Y
    Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Zhang Y; Lee LL; O'Dea R
    Biopharm Drug Dispos; 2004 Nov; 25(8):353-7. PubMed ID: 15378556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
    Dutta S; Reed RC
    Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
    Horne RL; Cunanan C
    J Clin Psychopharmacol; 2003 Apr; 23(2):176-81. PubMed ID: 12640219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
    Reed RC; Dutta S; Liu W
    Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs.
    Sommerville KW; Dutta S; Biton V; Zhang Y; Cloyd JC; Uthman B
    Clin Drug Investig; 2003; 23(10):661-70. PubMed ID: 17535081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
    Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
    Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Reed RC; Cavanaugh JH
    J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divalproex-ER pharmacokinetics in older children and adolescents.
    Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
    Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
    Roberts D; Easter D; O'Bryan-Tear G
    Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers.
    Zakeri-Milani P; Nemati M; Ghanbarzadeh S; Hamishehkar H; Valizadeh H
    Arzneimittelforschung; 2011; 61(8):439-43. PubMed ID: 21950147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.